Goldman Sachs Adds UnitedHealth to Conviction List, Maintains $435 Target

Goldman Sachs' positive report and $435 price target could increase institutional interest in the stock. Technical indicators point to a strong uptrend; although the RSI at 76 is approaching overbought territory, the MACD is giving a buy signal and the price is trading above the 20- and 50-day moving averages. The 4.8% rise in the last 24 hours indicates continued momentum. However, the RSI entering overbought territory also brings a short-term correction risk. Therefore, while the upward trend persists, caution is advisable.

Goldman Sachs' addition of UnitedHealth to its conviction list and its maintained $435 price target could boost investor confidence. GS shares have gained over 2% in the last 24 hours, with an RSI of 57.7 in neutral territory and a positive MACD above the signal line. The price trading above the 20- and 50-day moving averages supports a short-term bullish trend. Since the stock is not approaching overbought levels, there is potential for further upside. However, caution remains due to broader market uncertainties and the target price being below current levels.